Linked Life Data

12947220

Source:http://linkedlifedata.com/resource/pubmed/id/12947220

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2003-8-29
pubmed:abstractText
Allogeneic hematopoietic stem cell transplantation (HSCT) currently provides the only chance of curative therapy for many patients with hematological malignancies. Owing to the excess morbidity and mortality observed in less robust patients, this approach has traditionally been limited to younger patients without significant medical co-morbidities. Given the age profiles of patients with candidate hematological malignancies, a majority of patients are therefore ineligible for myeloablative therapy. Over the past few years the ability to achieve hematopoietic stem cell engraftment using immunosuppressive but non-myeloablative conditioning regimens has made it possible to consider a much broader group of patients for allogeneic HSCT. The discovery that the hematopoietic graft itself can contribute to the eradication of malignant cells through a graft-versus-malignancy (GVM) effect, independent of the conditioning regimen, has led to investigation of reduced intensity conditioning regimens for a variety of malignant diseases. Over the past few years there has been a dramatic increase in the number of patients undergoing reduced intensity conditioning for both malignant and nonmalignant conditions. This review will focus only on the use of such therapy for malignant disease.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:issn
0257-277X
pubmed:author
pubmed:issnType
Print
pubmed:volume
28
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1-11
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
Therapeutic applications of non-myeloablative hematopoietic stem cell transplantation in malignant disease.
pubmed:affiliation
Program in Transplantation Biology, Clinical Research Division, Fred Hutchinson Cancer Research Center, and Department of Medicine, Division of Oncology, University of Washington, School of Medicine, Seattle, Washington, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Review, Research Support, Non-U.S. Gov't